Source comparison
Comparison with Other GH Secretagogues in Muscle Research
CJC-1295’s muscle protein synthesis research profile can be contextualised relative to other GH secretagogues: Ipamorelin: The most selective GHS-R1a agonist — producing GH pulses through the ghrelin receptor without GHS-R1a-mediated side effects (ACTH/cortiso
This comparison does not assign a generated winner or score.
- CJC-1295’s muscle protein synthesis research profile can be contextualised relative to other GH secretagogues:
- Ipamorelin: The most selective GHS-R1a agonist — producing GH pulses through the ghrelin receptor without GHS-R1a-mediated side effects (ACTH/cortisol elevation, prolactin, appetite stimulation seen with less selective GHS-R1a agonists like GHRP-6). Combined CJC-1295 + Ipamorelin research — where GHRH receptor and GHS-R1a are co-activated through synergistic mechanisms — produces GH pulses larger than either compound alone. The combination protocol is a common experimental design in GH secretagogue muscle research.
- Sermorelin: The short-chain GHRH analogue (GHRH 1-29) without DAC technology — producing shorter-duration GH stimulation than CJC-1295. Research comparing these compounds in muscle anabolic protocols provides insight into whether sustained versus pulsatile GH stimulation produces equivalent muscle outcomes.
- GHRP-6: Ghrelin mimetic with additional appetite-stimulating effects through central ARC GHS-R1a. In muscle research, GHRP-6’s appetite stimulation can complicate interpretation of body composition outcomes by increasing caloric intake independently of direct muscle anabolic effects — a confound not present with GHRH analogues like CJC-1295.
- 🔗 Related Reading: For a comprehensive overview of CJC-1295 research, mechanisms, UK sourcing, and safety data, see our CJC-1295 UK Complete Research Guide 2026.
- 🔗 Also See: For a comparative overview of GH secretagogues including CJC-1295, Ipamorelin, Sermorelin and GHRP-6 research profiles, see our GH Secretagogue Comparison: Ipamorelin, CJC-1295, Sermorelin and GHRP-6 for Research UK 2026.